The image of Spodoptera frugiperda (fall armyworm) for today’s offering header is courtesy of Wikipedia. Health Friday is a series devoted to information about Big Pharma, vaccines, general health, and associated topics. There are Important Notifications from our host, Wolf Moon; the Rules of our late, good Wheatie; and, certain caveats from Yours Truly, of which readers should be aware. They are linked here. Note: AI-generated items in today’s offering will be cited as such. If readers wish to post AI-generated items in today’s discussion thread, they must cite their source. Thank you.

For previous information on NUVAXOVID, please see Part One of this series, here: https://www.theqtree.com/2026/10/02/health-friday-10-2-2026-open-thread-nuvaxovid-the-novavax-covid-19-bioweapon-vaccine-part-one/.

>>>>>>>>>>>>>>>>>>>>

NUVAXOVID, the Novavax COVID-19 Bioweapon “Vaccine”: Part Two

This article will discuss a sampling of more “details” from the Package Insert for Healthcare Providers for NUVAXOVID; followed by a presentation of the Patent for this injectable. The Package Insert for NUVAXOVID is here: https://www.fda.gov/media/186544/download. Let’s look at this statement on page 5, under the footnotes for section 6 ADVERSE REACTIONS:

**** In other words: it appears that there were TWO DIFFERENT manufacturing processes for the NUVAXOVID used in the clinical trials listed above the footnotes (seven clinical trials in all) — shades of the “Process 1” and “Process 2” manufacturing methods used by Pfizer-BioNTech for BNT162b2.

Study 1 (NCT04611802), which Yours Truly will call the first “NUVAXOVID Process 1 study” was conducted in the United States, Mexico, and Puerto Rico; Study 2 (NCT04583995), using the “NUVAXOVID Process 2 study”) was conducted in the United Kingdom; Study 3 (NCT04533300), another “NUVAXOVID Process 2 study”) was performed in South Africa; and, Study 4 (NCT 02368988), the final “NUVAXOVID Process 2 study”) was performed in the United States and Australia. Studies 1, 5, 6, and 7 used the “NUVAXOVID Process 1” manufacturing method. Information regarding the changes to the manufacturing processes for NUVAXOVID is found in this document, beginning on page 23 and continuing through page 31: https://www.ema.europa.eu/en/documents/assessment-report/nuvaxovid-epar-public-report_en.pdf, 4 January 2022. A screenshot of a portion of page 23 is below:

What follows, through page 31 of this document, is a “public-view description” of the multiple changes to the manufacturing process for NUVAXOVID: changes that occurred while clinical studies were ongoing; changes that occurred due to the “vaccine” (NVX-CoV2373, the “other name” for NUVAXOVID) being manufactured by at least two different entities in two different countries; changes that resulted in different types of formulations; and more. Were the human study subjects in the seven studies listed above informed that the NUVAXOVID (NVX-CoV2373) that was injected into them could have been manufactured in, for example, Japan or India? That the composition of the formulation that was injected into them could be different from one human study subject to another? Did the study subjects have to sign off on the above?

Looking “further afield” regarding the (at least two; perhaps, more?) manufacturing processes for NUVAXOVID, Yours Truly found this: https://www.mci.edu/en/news-filter-en/228-researchernews/4068-nuvaxovid-new-vaccine-explained, ” Nuvaxovid – the new subunit SARS-CoV-2 vaccine”, Carmen Nussbaumer, 28 February 2022 (Innsbruck, Austria.) A screenshot of the section, “What comprises the Nuvaxovid vaccine?” is below. This article confirms that the spike protein is the basis for NUVAXOVID. It also confirms that the spike protein is “inserted” into a virus created from the Spodoptera frugiperda Sf9 cell line, which is then introduced into the body — thus, two different viruses are used: the manipulated “baculovirus” that is inserted into the Sf9 insect cells + the spike protein of the SARS-CoV-2 virus.:

The Package Insert for Healthcare Providers for NUVAXOVID (link above) appears to focus on Study 1 (NCT04611802, https://clinicaltrials.gov/study/NCT04611802), which was conducted in the United States, Mexico, and Puerto Rico. On page 8 of the Fact Sheet, for example, there is a breakdown of the types and percentages of study subjects affected by adverse reactions to NUVAXOVID. The figures on page 8 are, in Yours Truly’s opinion, revealing: one sees that the numbers of Study 1 subjects who had adverse reactions to this “vaccine” far outweigh the numbers of Study 1 subjects who were given the saline solution placebo injections. A screenshot of a portion of page is below:

Grade 3 adverse reactions include those which interfere with normal daily activities; which cause a high degree of pain; and so on. Grade 4 adverse reactions include those which require Emergency Room visits or hospitalization; which indicate tissue death (necrosis); and more. One more detail in the Package Insert for Healthcare Providers for NUVAXOVID: on page 42, the (“official”, per the Package Insert) manufacturer of this “vaccine” is Sanofi (also known as Sanofi-Pasteur.) A screenshot of page 42 is below:

Sanofi has a website devoted to NUVAXOVID: https://www.nuvaxovid.com/. This website states that the product does not contain SARS-CoV-2:

>>>>>>>>>>>>>>>>>>>>

The information regarding the differences in manufacturing processes among what Yours Truly will call the “NUVAXOVID Process 1” and the “NUVAXOVID Process 2” led one to look up the Patent for NUVAXOVID: https://patents.google.com/patent/US11253586B2/en, “Coronavirus vaccine formulations”. A screenshot of the Title and Date Summary of the Patent is below:

A screenshot of Claim 1 is below:

Which, by the way, appears to confirm that: the SARS-CoV-2 virus is NOT found in nature; that the spike protein of this virus is the foundation for NUVAXOVID; and, that elements of the spike protein were modified for use in the “vaccine” (modRNA.) Which also appears to contradict the statement on the Sanofi-sponsored NUVAXOVID website (link above, and image from the website) that there is no SARS-CoV-2 in the product.

Some other details from the Patent: One: Fig. 4 and Fig. 5, regarding two SARS-CoV-2 polypeptides (BV2365 and BV2373) which bind well to the ACE2 receptor enzymes in the body. These receptors are crucial for controlling blood pressure, wound healing, and inflammation (https://www.asbmb.org/asbmb-today/science/051620/what-is-the-ace-2-receptor, 16 May 2020.) Apparently, the inventors of NUVAXOVID spent time and effort in manipulating BV2365 and BV2373 to get the results they wanted: SARS-CoV-2 virus elements that would bind as completely as possible to the ACE2 receptors in the body. Two: there are several types of “detergents” that can be used (“in embodiments” is the language in the Patent) in NUVAXOVID to “scrub clean” the surface of body cells to assist the “vaccine’s” entry into these cells. Two such detergents are NP-9 and polysorbate 80 (PS80.) PS80 was one chosen for the U.S. version of this “vaccine” (see the Package Insert [link above], section 11 DESCRIPTION.)

**** The combination of the spike protein elements + PS80 make up the nanoparticle used in NUVAXOVID (Claim 6): it appears that the PS80 surfactant detergent “scrubs clean” the surface of the ACE2 receptors; so that the manipulated BV2365 and BV2373 enzymes from the spike protein can gain entry into these receptors: therefore interfering with their normal functions of controlling blood pressure, wound healing, inflammation, and other processes. In addition, the PS80 + spike protein which makes up the nanoparticle for NUVAXOVID allows the spike protein to be “mainlined” into every cell in the body.

But wait, there’s more! Reading through more of the Patent, it is apparent that: One: other forms of CoV (coronavirus) elements can be used (MERS, SARS-CoV), either alone OR IN COMBINATION with the spike protein from SARS-CoV-2, in NUVAXOVID; Two: it appears that the BV2373 enzyme from the SARS-CoV-2 virus is the “prime instigator” used in the “vaccine”; Three: that the “vaccine” is formulated to specifically attack the CD4 – CD8 cells of the body; Four: that ALUMINUM salts can also be used as an adjuvant in the “vaccine”; Five: that the use of the Matrix-M adjuvant (made from the soapbark tree) in the “vaccine” MAY LEAVE TRACE ELEMENTS of the manufacturing process for this adjuvant; and, Six: that the Matrix-M adjuvant can comprise AS MUCH AS 85% of the “vaccine” formulation. Note: adjuvants are used in “vaccines” to increase the response in body of the “vaccinated” person.

>>>>>>>>>>>>>>>>>>>>

**** What we have now is the following: A COVID-19 bioweapon “vaccine”, called NUVAXOVID. This “vaccine”: may include not only the spike protein from the SARS-CoV-2 virus, but ALSO elements from other coronaviruses (MERS, or SARS-CoV, or others); which may include one OR more detergents (NP-9, PS80. or others); which may include UP TO 85% of a lab-created compound called Matrix-M, an adjuvant, lab-created from elements of the soapbark tree; which MAY also include aluminum salts as an adjuvant; which includes a “baculovirus” that is lab-created from the Sf9 cells of Spodoptera frugiperda (fall armyworm), a voracious crop destroyer insect; which is manufactured under “partnership” with Sanofi, or with FUJIFILM (Japan), or in India (the latter two locations were where the NUVAXOVID used in clinical trials were manufactured; it is unknown if these two locations are still being used to manufacture the “vaccine”); which is a “vaccine” that CROSSES THE BLOOD-BRAIN BARRIER, in addition to entering into every cell of the “vaccinated” body; which allows the PS80 + spike protein nanoparticle in NUVAXOVID to be “mainlined” into every cell in the body; and, which contains at least one chemical compound — methyl-alpha-D-mannopyranoside) that is “Not for drug or household use” (https://www.tcichemicals.com/OP/en/p/M0368; click on “Safety & Regulations” tab; then click “Safety Data Sheet (SDS)” in English); and, finally, that the FDA-issued Package Insert for Healthcare Providers only contains the information that Novavax has given to the FDA. NUVAXOVID is a modRNA COVID-19 bioweapon “vaccine.” It is NOT a “safer alternative” to COMIRNATY, to SPIKEVAX, to mNEXSPIKE, or to any other COVID-19 bioweapon “vaccine.” In fact, NUVAXOVID, in Yours Truly’s opinion, could be slightly more dangerous than the other COVID-19 bioweapon “vaccines” — because the nanoparticle used in this “vaccine” is made up of a detergent + the elements of the SARS-CoV-2 virus spike protein itself (manipulated with Sf9 insect “baculovirus”.)

The FDA has granted full approval for this “vaccine.” Who, reading the information in today’s offering, along with that in Part One of the NUVAXOVID series, would allow this product to be injected into their body — or into the body of their child?

Peace, Good Energy, Respect: PAVACA1

(Intellectual Property Disclaimer and Notice: Except for the linked URLs and other items that are available on the Internet, the ideas and/or opinions in today’s offering are by PAVACA1 (M.E. Forbes, aka M.E.C. Forbes.) Credit must be given to PAVACA1 if ideas and/or opinions in today’s offering are used by other blog writers; by podcasters; or in print or social media.)